SCHEMBL2885397

SCHEMBL2885397

Cc1cc(C)n(-c2nc(Nc3ccc(Cl)cc3)cnc2NC(=O)OC(C)(C)C)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL6 P41182 1/20 0.46
MAPT P10636 4/20 0.44
TP53 P04637 1/20 0.43
KCNN2 Q9H2S1 1/20 0.40
KCNN3 Q9UGI6 1/20 0.40
P2RX3 P56373 2/20 0.39
PTGER1 P34995 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
LMNA P02545 1/20 0.38
CYP2C9 P11712 1/20 0.38
POLB P06746 1/20 0.38
XBP1 P17861 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3650690 0.87 BCL6 (0.52) BCL6MAPTTP53KCNN2KCNN3
SCHEMBL13067901 0.87 BCL6 (0.46) BCL6MAPTTP53KCNN2KCNN3
SCHEMBL2893435 0.80 TSHR (0.39) MAPTTP53KDM4EALDH1A1MEN1
SCHEMBL2890629 0.78 BCL6 (0.53) BCL6MAPTTP53KCNN2KCNN3
SCHEMBL2890844 0.75 BCL6 (0.54) BCL6MAPTTP53KCNN2KCNN3
SCHEMBL2889491 0.75 BCL6 (0.47) BCL6MAPTTP53KCNN2KCNN3
SCHEMBL2890777 0.74 BCL6 (0.51) BCL6MAPTTP53KCNN2KCNN3
SCHEMBL2891251 0.74 BCL6 (0.51) BCL6MAPTTP53KCNN2KCNN3
SCHEMBL3651956 0.74 BCL6 (0.44) BCL6MAPTTP53KCNN2KCNN3
SCHEMBL2885400 0.73 BCL6 (0.49) BCL6MAPTTP53KCNN2KCNN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415358-B2 Pyrazine derivatives and their use as potassium channel modulators NEUROSEARCH A/S (DK) 2013-04-09 US disclosed
US-8415358-B2 Pyrazine derivatives and their use as potassium channel modulators NEUROSEARCH A/S (DK) 2013-04-09 US disclosed
US-8415358-B2 Pyrazine derivatives and their use as potassium channel modulators NEUROSEARCH A/S (DK) 2013-04-09 US disclosed
US-20100286161-A1 PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS, INC. 2010-11-11 US disclosed
US-20100286161-A1 PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS, INC. 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286161-A1 PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS KCNJ2, KCNQ5, KCNA5 BCL6 3342/4885MAPT 1432/4885TP53 3577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.